Stayble Therapeutics AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported revenue was SEK 0.003 million compared to SEK 0.034 million a year ago. Net loss was SEK 7.04 million compared to SEK 5.88 million a year ago. Basic loss per share from continuing operations was SEK 0.22 compared to SEK 0.42 a year ago.
For the nine months, revenue was SEK 0.009 million compared to SEK 0.257 million a year ago. Net loss was SEK 17.45 million compared to SEK 19.97 million a year ago. Basic loss per share from continuing operations was SEK 0.73 compared to SEK 1.44 a year ago.